Table 1.

Patient characteristics and response to pembrolizumab

	Patient
	1	2	3	4	5
Prior therapies, n	2	4	2	3	2
Prior anti-CD19 CAR-T cells	No	Yes	No	No	No
Cycles of pembrolizumab, n	32	9	14	3	5
Best radiographic response	CR (ongoing*)	CR (ongoing*)	PR	PD	PD

PD, progressive disease.

^*For patient 1, CR >2 years; for patient 2, CR >6 months.